Dynamic susceptibility contrast (DSC) MRI for Pilocytic Astrocytoma

Phase-Based Progress Estimates
Pilocytic Astrocytoma+8 More
Dynamic susceptibility contrast (DSC) MRI - Device
< 65
All Sexes
What conditions do you have?

Study Summary

This trial will use MRI and blood tests to develop a way to measure and identify when the blood brain barrier is most disrupted after treatment for brain tumors, in order to improve treatment.

Eligible Conditions
  • Pilocytic Astrocytoma
  • Anaplastic Astrocytoma (AA)
  • Oligodendroglioma
  • Mixed Gliomas
  • Optic Nerve Glioma
  • Glioblastoma
  • Oligoastrocytoma, Mixed
  • Glioma
  • Astrocytoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pilocytic Astrocytoma

Study Objectives

4 Primary · 3 Secondary · Reporting Duration: Up to 5 years

1 year from MLA
Arm B only: Quality of life (QOL)
Correlation of MR imaging with peritumoral BBB disruption
Serum biomarkers of peritumoral BBB disruption
6 months
Arm B only: Progression-free survival (PFS)
Predictive value of the peritumoral permeability score for patient outcome as measured by PFS
Up to 5 years
Arm A only: Overall survival (OS)
Arm A only: Progression-free survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Pilocytic Astrocytoma

Trial Design

2 Treatment Groups

Arm A (MRI-guided laser ablation)
1 of 2
Arm B (MRI-guided laser ablation, doxorubicin, etoposide)
1 of 2
Experimental Treatment

12 Total Participants · 2 Treatment Groups

Primary Treatment: Dynamic susceptibility contrast (DSC) MRI · No Placebo Group · Phase 2

Arm A (MRI-guided laser ablation)Experimental Group · 3 Interventions: Dynamic susceptibility contrast (DSC) MRI, MRI-guided laser ablation, Dynamic contrast-enhanced (DCE) MRI · Intervention Types: Device, Device, Device
Arm B (MRI-guided laser ablation, doxorubicin, etoposide)Experimental Group · 5 Interventions: Dynamic susceptibility contrast (DSC) MRI, MRI-guided laser ablation, Dynamic contrast-enhanced (DCE) MRI, Doxorubicin, Etoposide · Intervention Types: Device, Device, Device, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,789 Previous Clinical Trials
2,271,864 Total Patients Enrolled
Joshua Rubin, M.D., Ph.D.Principal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
Margaret Shatara, M.D.Principal InvestigatorWashington University School of Medicine

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The neurosurgeon determined that the recurrent pediatric brain tumors were candidates for MLA.
A patient must wait at least twelve weeks after finishing radiation treatment before enrolling in a study, unless there is evidence of tumor recurrence
had been lacking There was a lack of definitive evidence that tumors had progressed through MRI scans.
based on size, location, and other features will be treated with MLA
Age 3 to ≤ 21 years old.
This person's Karnofsky/Lansky performance status is ≥ 60%.
The text describes recurrent lesions that are determined by a neurosurgeon to be appropriate for MLA.
The person must have a shortening fraction of 27% or higher or a left ventricular ejection fraction of 50% or higher by echocardiogram within the past year prior to registration.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.